Abstract
CCAAT enhancer-binding protein (C/EBP) transcription factors regulate adipocyte differentiation, and recent evidence suggests that osteoblasts and adipocytes share a common pluripotent progenitor in bone marrow. However, little is known about the role of C/EBP transcription factors in the control of osteoblast differentiation or function. In this study, the function of C/EBP transcription factors was disrupted in osteoblast lineage cells by overexpressing a naturally occurring dominant negative C/EBP isoform. Expression of FLp20C/EBPbeta was driven by a 3.6-kb Col1a1 promoter/first intron construct, and four transgenic (TG) mouse lines were established. Northern blotting and reverse transcription-PCR indicated that the transgene was targeted to bone, with lower levels of expression in lung, skin, and adipose tissue. TG mice from two lines showed reduced body weight compared with wild type littermates. All TG lines showed evidence of osteopenia, ranging from mild to severe, as evidenced by reduced trabecular bone volume. Severely affected lines also showed reduced cortical bone width. Dynamic histomorphometry demonstrated an associated decrease in mineral apposition and bone formation rates. Long bones and calvariae of TG mice showed reduced COL1A1 and osteocalcin mRNA levels and increased bone sialoprotein mRNA, consistent with an inhibition of terminal osteoblast differentiation. Ex vivo analysis of primary osteoblast differentiation showed similar effects on marker expression and reduced expression of the mature osteoblast marker Col2.3-green fluorescent protein, demonstrating a cell-autonomous effect of the transgene. These data suggested that C/EBP transcription factors may be important determinants of osteoblast function and bone mass.
Highlights
A wealth of recent evidence suggests that the osteoblast and adipocyte lineages are closely related, diverging from a common pluripotent progenitor cell (16 –18)
We demonstrated that FLp20C/EBP bound to an interleukin-6 promoter probe containing a known CCAAT enhancer-binding protein (C/EBP) binding site from the interleukin-6 promoter (Ϫ171/Ϫ142) (Fig. 1b)
In the present study we have demonstrated that TG mice with pOBCol3.6-targeted overexpression of p20C/EBP show evidence of osteopenia ranging from mild to severe
Summary
C/EBP, CCAAT enhancer-binding protein; DEXA, dual energy x-ray absorptiometry; microCT, microcomyl-terminal leucine zipper dimerization domain and an adjacent highly conserved basic DNA binding domain [1, 2]. We have used a loss-of-function strategy to test the hypothesis that C/EBP transcription factors play a role in osteoblast differentiation and/or function Toward this end, a naturally occurring dominant negative C/EBP isoform (p20C/EBP, LIP) [19] has been targeted to cells of the stromal/osteoblast lineage using a 3.6-kb Col1a1 promoter fragment (pOBCol3.6-FLp20C/EBP). A naturally occurring dominant negative C/EBP isoform (p20C/EBP, LIP) [19] has been targeted to cells of the stromal/osteoblast lineage using a 3.6-kb Col1a1 promoter fragment (pOBCol3.6-FLp20C/EBP) Mice expressing this transgene show evidence of osteopenia secondary to reduced bone formation, suggesting a role for C/EBP transcription factors in the regulation of osteogenesis
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.